Anchiano Therapeutics Ltd.

4.71+0.2400+5.37%Vol 25.04M1Y Perf 622.84%
Mar 16th, 2021 16:00 DELAYED
BID5.46 ASK5.54
Open5.10 Previous Close4.47
Pre-Market- After-Market-
 - -  - -%
Target Price
1.00 
Analyst Rating
Hold 3.00
Potential %
- 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12 mo.
-/-/- 
Value Ranking
 —    -
Insiders Value % 3/6/12 mo.
-/-/- 
Growth Ranking
 —    -
Insiders Shares Cnt. % 3/6/12 mo.
-/-/- 
Income Ranking
 —    -
Market Cap34.95M 
Earnings Rating
Neutral
Price Range Ratio 52W %
41.83 
Earnings Date
6th May 2021

Today's Price Range

4.608.20

52W Range

0.510010.55

Summary:

Buy

Technical Indicators: Buy
Moving Averages: Strong Buy
Performance
1 Week
0.00%
1 Month
14.88%
3 Months
129.76%
6 Months
299.15%
1 Year
622.84%
3 Years
-
5 Years
-
10 Years
-

TickerPriceChg.Chg.%
ANCN4.710.24005.37
AAPL132.992.63002.02
GOOG2 285.8820.44000.90
MSFT255.852.60001.03
XOM55.87-0.1300-0.23
WFC40.500.47001.17
JNJ161.25-1.7200-1.06
FB312.46-0.5600-0.18
GE13.600.15001.12
JPM156.281.16000.75
Earnings HistoryEstimateReportedSurprise %
Q04 2020-0.50-0.2550.00
Q03 2020-0.45-0.3522.22
Q02 2020-0.55-0.4518.18
Q01 2020-0.55-0.4125.45
Q04 2019-0.131.991.63K
Q03 2019-0.15-2.26-1 406.67
Q02 2019-0.78-0.0593.59
Q01 2019--3.50-
Earnings Per EndEstimateRevision %Trend
12/2020 QR-0.500.00-
12/2020 QR-0.509.09Positive
12/2021 FY-3.100.00-
12/2022 FY-3.100.00-
Next Report Date6th May 2021
Estimated EPS Next Report-
Estimates Count-
EPS Growth Next 5 Years %-
Volume Overview
Volume25.04M
Shares Outstanding7.42M
Trades Count115.83K
Dollar Volume1.69M
Avg. Volume3.15M
Avg. Weekly Volume6.02M
Avg. Monthly Volume4.79M
Avg. Quarterly Volume2.67M

Anchiano Therapeutics Ltd. (NASDAQ: ANCN) stock closed at 4.71 per share at the end of the most recent trading day (a 5.37% change compared to the prior day closing price) with a volume of 25.04M shares and market capitalization of 34.95M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 16 people. Anchiano Therapeutics Ltd. CEO is Neil Cohen.

The one-year performance of Anchiano Therapeutics Ltd. stock is 622.84%, while year-to-date (YTD) performance is 172.25%. ANCN stock has a five-year performance of %. Its 52-week range is between 0.51 and 10.55, which gives ANCN stock a 52-week price range ratio of 41.83%

Anchiano Therapeutics Ltd. currently has a PE ratio of -2.00, a price-to-book (PB) ratio of 25.21, a price-to-sale (PS) ratio of -, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -89.53%, a ROC of -184.11% and a ROE of -125.60%. The company’s profit margin is -%, its EBITDA margin is -%, and its revenue ttm is $0.00 , which makes it $0.00 revenue per share.

Of the last four earnings reports from Anchiano Therapeutics Ltd., there were 4 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $0.00 for the next earnings report. Anchiano Therapeutics Ltd.’s next earnings report date is 06th May 2021.

The consensus rating of Wall Street analysts for Anchiano Therapeutics Ltd. is Hold (3), with a target price of $1, which is 0.00% compared to the current price. The earnings rating for Anchiano Therapeutics Ltd. stock is Neutral (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Anchiano Therapeutics Ltd. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Anchiano Therapeutics Ltd. has a Buy technical analysis rating based on Technical Indicators (ADX : 47.41, ATR14 : 1.02, CCI20 : 31.13, Chaikin Money Flow : -0.19, MACD : 0.28, Money Flow Index : 93.04, ROC : 17.67, RSI : 60.52, STOCH (14,3) : 56.68, STOCH RSI : 1.00, UO : 43.53, Williams %R : -43.32), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Anchiano Therapeutics Ltd. in the last 12-months were:

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
2 (100.00 %)
2 (100.00 %)
2 (100.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingHold
3.00
Hold
3.00
Hold
3.00

Anchiano Therapeutics Ltd.

Anchiano Therapeutics Ltd is an Israel based pivotal-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of novel therapies to treat cancer in areas of unmet need. It focuses on lung cancer, colorectal cancer, and pancreatic cancer.

CEO: Neil Cohen

Telephone: +972 25486555

Address: 5 Kiryat Hamada Street, Jerusalem 9777401, , IL

Number of employees: 16

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

75%25%

Bearish Bullish

57%43%

Bearish Bullish

55%45%

News

Stocktwits